Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if it is feasible and safe to use the REG1 Anticoagulation System instead of unfractionated heparin during percutaneous coronary intervention (PCI) in subjects with coronary artery disease (CAD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI

NCT01848106

Coronary Artery Disease

TERMINATED PHASE3

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

NCT00932100

Acute Coronary Syndrome (ACS)

COMPLETED PHASE2

Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse

NCT01336348

ST Segment Elevation Myocardial Infarction

COMPLETED PHASE3

Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not

NCT04927949

ST-elevation Myocardial Infarction

COMPLETED PHASE4

Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)

NCT00251823

Myocardial Infarction

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study drug, REG1, is the first specific, direct-acting, antidote-controlled anticoagulant ever described. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), put patients at high risk for therapy-related bleeding complications. REG1 is being developed initially to increase therapeutic flexibility and improve patient outcomes in coronary revascularization procedures.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched antidote. The REG1 anticoagulant component (RB006) is a single-stranded, nucleic acid aptamer. RB006 selectively and potently binds to and inhibits Factor IXa, a protein critical to blood coagulation. The antidote component, RB007, is a complementary nucleic acid that binds to and neutralizes RB006. The binding of RB007 to RB006 causes the predictable and rapid reversal of the RB006 effect and allows the patient's blood to return to normal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Unfractionated Heparin

Group Type ACTIVE_COMPARATOR

Unfractionated Heparin

Intervention Type DRUG

Heparin will be administered per standard of care at sites

REG1 Partial Rev.

REG1 with partial reversal

Group Type EXPERIMENTAL

REG1

Intervention Type DRUG

ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.

REG1 Total Rev.

REG1 with total reversal

Group Type EXPERIMENTAL

REG1

Intervention Type DRUG

ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

REG1

ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.

Intervention Type DRUG

REG1

ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.

Intervention Type DRUG

Unfractionated Heparin

Heparin will be administered per standard of care at sites

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

UFH

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females scheduled for non-urgent elective PCI (who do not have certain cardiac parameters) and have not been treated with UHF prior to PCI.
* Subject able to give informed consent and comply with the protocol.
* Negative urine pregnancy test or documented surgical sterilization or menopausal.

Exclusion Criteria

* Subject weight \>120 kg.
* Recent acute coronary syndrome with elevated cardiac markers or ST segment depression at rest.
* Evidence of clinical instability
* Angiographic high-risk.
* A contraindication to anticoagulation or increased risk of bleeding.
* Use of prohibited medications or investigational drugs prior to the study.
* Clinically significant abnormal laboratory findings.
* Planned use of femoral sheath greater than a certain size.
* Known allergy or intolerance to drugs mandated by the study.
* Use of devices other than angioplasty balloons and coronary stents.
* A history of licit drug abuse or illicit drug use or current evidence of such abuse.
* Any other factor that the Investigator feels would put the subject at increased risk if participating in the protocol.
* Lactation.
* Currently enrolled in this or another clinical trial (with some exceptions).
* Participation in an investigational drug or device trial in the past 30 days.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No